Zydus announces positive Phase 2 Proof-of-Concept of NLRP3 …
WEBSep 7, 2022 · First Phase 2 Proof-of-Concept (POC) study demonstrating rapid clinical improvement and remission within days when Cryopyrin Associated Periodic Syndrome (CAPS) patients with flare ups were treated with ZYIL1, a …
Xencor Regains CD20 x CD3 Bispecific T-Cell Engager
WEBJun 13, 2024 · Plamotamab is an investigational XmAb® bispecific antibody that contains both a CD20 binding domain and a cytotoxic T-cell binding domain (CD3). Engagement of CD3 by plamotamab activates T cells for highly potent and targeted killing of CD20-expressing cells. Data presented from a Phase 1 clinical study …
The convergence of Antibody-Drug Conjugates and Targeted …
WEBSep 4, 2024 · STUTTGART, Germany I September 04, 2024 I La Merie Publishing released its newest report with a landscape description and analysis of degrader-antibody conjugate (DAC) stakeholders, platform technologies, development and discovery pipelines and partnering deals from an industry perspective as of September 2024:. Degrader-Antibody Conjugates 2024: A Landscape Analysis of Stakeholders ...
PipelineReview.com. Biopharmaceutical News & Clinical Trials
WEBPipelineReview.com is powered by La Merie Business Intelligence For immediate assistance, please call us during business hours: Mon-Fri 10:00am - 05:00pm; GMT+01 La Merie Publishing - Ulrich Martin Veinat Puigsec - Can Magí s/n | 17862 Vallfogona de Ripollès | Spain | T +34-87-200 1365 | Email [email protected]
Chengdu Origen and Vanotech Announce First Patient
WEBNov 21, 2023 · Clinical trial of KH631 evaluates single administration gene-therapy treatment for wet AMD. CHENGDU, China and ROCKAWAY, NJ, USA I November 20, 2023 I Chengdu Origen Biotechnology Co., Ltd. (“Chengdu Origen”) and Vanotech Ltd. (“Vanotech”) announced today the first patient dosed in the VAN-2201 multi-center Phase 1 clinical trial evaluating treatment with KH631 for patients with wet ...
Crossbow Therapeutics Selects First Development Candidate from …
WEBMar 6, 2024 · CBX-250 is a first-in-class, potent, and specific T-cell engager for the treatment of myeloid leukemia. Abstract summarizing preclinical characteristics of CBX-250 selected for an oral presentation at the American Association for Cancer Research (AACR) 2024 Annual Meeting
Meissa Announces First Dosing in Phase 2 Study of Intranasal Live ...
WEBJan 21, 2021 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of our expertise.
All news - Pipelinereview
WEB6 days ago · PipelineReview.com is powered by La Merie Business Intelligence For immediate assistance, please call us during business hours: Mon-Fri 10:00am - 05:00pm; GMT+01 La Merie Publishing - Ulrich Martin Veinat Puigsec - Can Magí s/n | 17862 Vallfogona de Ripollès | Spain | T +34-87-200 1365 | Email [email protected]
Principia Presents Phase 1 Data of PRN1371 in Patients with …
WEBMay 21, 2019 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of our expertise.
Amberstone Biosciences Secures $12 Million Series A Financing to ...
WEBJan 3, 2022 · LAGUNA HILLS, CA, USA I January 03, 2021 I Amberstone Biosciences (www.amberstonebio.com), an emerging biotherapeutics company with unique expertise in conditionally active immunotherapeutics, today announced the completion of a $12 million Series A financing round.The funding was led by Viva BioInnovator, Co-win Ventures and Sinovation Ventures, with additional support from ChangRong Capital ...